TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25502863
Drug: Amatuximab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amatuximab (200 mg/m2)
Study: 25502863
Drug: Amatuximab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amatuximab (50 mg/m2)
Study: 25503302
Drug: Vandetanib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (200 mg) plus sirolimus (2 mg)
Study: 25503750
Drug: Combined inhaled
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined inhaled medication
Study: 25503901
Drug: Implant-supported restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported restorative therapy
Study: 25504157
Drug: Desmopressin tablet
Normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin tablet (once daily)
Study: 25504813
Drug: Korean Red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng at doses of 3 g/day
Study: 25505693
Drug: Add-on lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on lithium (600 to 1,800 mg/day)
Study: 25505693
Drug: Lithium in
Normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium in combination with quetiapine XR
Study: 25510388
Drug: MCC-CRM followed
Normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MCC-CRM followed by MCC-TT vaccine
Study: 25510388
Drug: Two MCC-CRM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two MCC-CRM vaccines
Study: 25510388
Drug: Two MCC-TT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two MCC-TT vaccines
Study: 25510388
Drug: MCC-TT followed
Normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MCC-TT followed by MCC-CRM vaccine
Study: 25511105
Drug: Serelaxin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (30 μg kg(-1) day(-1) via intravenous infusion for 24 hours)
Study: 25511129
Drug: Hypnotic relaxation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic relaxation suggestion
Study: 25511783
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with stages 3-4 renal dysfunction (GFR <60 mL/min/1.73 m(2))
Study: 25512030
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and trastuzumab neoadjuvant chemotherapy (NC) for 24 weeks, followed by 1 year adjuvant trastuzumab ± hormonal and/or radio-therapy.
Study: 25512030
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and trastuzumab neoadjuvant chemotherapy (NC) for 24 weeks.
Study: 25512030
Drug: Trastuzumab-mediated antibody-dependent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab-mediated antibody-dependent cell cytotoxicity (ADCC).
Study: 25512422
Drug: Rifapentine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine (600 mg) with bedaquiline (400 mg)
Study: 25512422
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg) with bedaquiline (400 mg)
Study: 25512839
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (three weekly sessions for four weeks)
Study: 25512839
Drug: Conventional occlusal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occlusal splint therapy (worn for four weeks)
Study: 25512839
Drug: Massage +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage + Conventional occlusal splint therapy (three weekly sessions for four weeks and occlusal splint worn for four weeks)
Study: 25512839
Drug: Silicone occlusal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone occlusal splint therapy (worn for four weeks)
Study: 25512874
Drug: Closed loop
Normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed loop with diluted insulin aspart (CL_Dil; 20 IU/mL)
Study: 25512874
Drug: Closed loop
Normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed loop with standard aspart (CL_Std; 100 IU/mL)
Study: 25514427
Drug: Low IL-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low IL-8 levels (L group, n = 335)
Study: 25516773
Drug: Paracetamol/naproxen (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/naproxen (n = 35)
Study: 25516773
Drug: Paracetamol/CR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/CR oxycodone for 24 hours (n = 35)
Study: 25516773
Drug: Paracetamol/CR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/CR oxycodone for 48 hours (n = 35)
Study: 25516774
Drug: Diclofenac sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac sustained release 75 mg once daily
Study: 25516890
Drug: MK-2206 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 at 135 mg weekly and selumetinib at 100 mg once daily
Study: 25518864
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Morris-Marshall score and S-100B bulk release
Study: 25519810
Drug: Bimatoprost 0.01%
Normalized name: BIMATOPROST 0.01% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.01% once daily
Study: 25521357
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bevacizumab and first-line paclitaxel with favorable genetic profile (VEGFR-2 rs11133360 and IL-8 rs4073)
Study: 25521357
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bevacizumab and first-line paclitaxel with unfavorable genetic profile (VEGFR-2 rs11133360 and IL-8 rs4073)
Study: 25521398
Drug: Dacomitinib at
Normalized name: dacomitinib
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dacomitinib at 45 mg once daily
Study: 25521773
Drug: Standard intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intraoperative dose of morphine
Study: 25523604
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea gel (test group)
Study: 25524800
Drug: Blinatumomab (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (9 μg/day for the first 7 days and 28 μg/day thereafter) by continuous intravenous infusion over 4 weeks every 6 weeks (up to five cycles)
Study: 25526776
Drug: 6-mercaptopurine (6MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine (6MP) 55 mg/m² per day and methotrexate 15 mg/m² per week
Study: 25527007
Drug: wXELIRI (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: wXELIRI (weekly irinotecan 90 mg/m² on day 1 and capecitabine 1200 mg/m² twice daily on days 1-5)
Study: 25527007
Drug: wXELIRI (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: wXELIRI (weekly irinotecan and capecitabine)
Study: 25529193
Drug: BI 831266
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 831266 (130 mg)
Study: 25529193
Drug: BI 831266
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 831266 (various doses 4-130 mg)
Study: 25529193
Drug: BI 831266
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 831266 (various doses)
Study: 25529193
Drug: BI 831266
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 831266 (32 mg)
Study: 25529339
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose MSCs (1 million cells/kg PBW)
Study: 25529339
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose MSCs (5 million cells/kg PBW)
Study: 25529339
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose MSCs (10 million cells/kg PBW)
Study: 25529339
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of MSCs
Study: 25531808
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) injection in forearm and deltoid
Study: 25531808
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injection in deltoid
Study: 25531808
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) injection in forearm
Study: 25531960
Drug: ALO-02 (oxycodone-hydrochloride/naltrexone-hydrochloride)
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO-02 (oxycodone-hydrochloride/naltrexone-hydrochloride)
Study: 25533729
Drug: Twelve-week weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve-week weight loss intervention, details on dosage and specific methods not provided.
Study: 25533886
Drug: SBT/ABPC 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBT/ABPC 3 g QID intravenously for 3-14 days
Study: 25535009
Drug: G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G allele of rs7549184
Study: 25535041
Drug: HIV medication
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV medication adherence intervention program
Study: 25535294
Drug: US smokers;
Approvals — FDA: no, EMA: no, PMDA: no
Description: US smokers; urine NNAL excretion
Study: 25535398
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) added to standard therapy
Study: 25538323
Drug: Exogenous intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous intravenous administrations of GLP-1
Study: 25538323
Drug: Exogenous intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous intravenous administrations of GIP
Study: 25538323
Drug: Exogenous intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous intravenous administrations of GLP-1 and GIP
Study: 25540064
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg/day (n = 63)
Study: 25540064
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg/day (n = 28, CP 2L)
Study: 25540064
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg/day (n = 7, advanced-phase 2L)
Study: 25540064
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg/day (n = 11, 3L)
Study: 25545153
Drug: G-CSF priming,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF priming, clofarabine (30 mg m(-2) day(-1) × 5), and cytarabine (2 g m(-2) day(-1) × 5)
Study: 25545153
Drug: G-CSF priming,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF priming, clofarabine, and cytarabine
Study: 25546176
Drug: Pre-bolus low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-bolus low-dose contrast injection (1.3 mL and 0.05 mmol/kg of gadobenate dimeglumine)
Study: 25552401
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day gefitinib and 400 mg/day vorinostat
Study: 25552401
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day gefitinib and 400 mg/day vorinostat in EGFR-mutant NSCLC
Study: 25553059
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity index (SI) calculated from the minimal model.
Study: 25555214
Drug: Biological pathways
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological pathways and genes associated with adipose tissue lipogenesis in MNO subjects
Study: 25555214
Drug: Biological pathways
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological pathways and genes associated with adipose tissue lipogenesis in MAO subjects
Study: 25555267
Drug: Calcium-channel blockers
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel blockers use
Study: 25555354
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg/day) for 7 days
Study: 25555354
Drug: Both aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both aspirin and EPA+DHA for another 7 days
Study: 25555420
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg orally once daily for 28-day cycles until disease progression or limiting toxicities
Study: 25556716
Drug: IGN523 (anti-CD98
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGN523 (anti-CD98 antibody)
Study: 25556837
Drug: Concomitant CYP3A4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant CYP3A4 inhibitors
Study: 25557329
Drug: Multimodal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesic regimen (gabapentin, ketorolac, dexamethasone, acetaminophen, ibuprofen)
Study: 25558980
Drug: Intraoperative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative dose of morphine
Study: 25560174
Drug: Dalfampridine-ER 5
Normalized name: Dalfampridine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine-ER 5 mg
Study: 25560174
Drug: Dalfampridine-ER 10
Normalized name: Dalfampridine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine-ER 10 mg
Study: 25560203
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anesthesia using 0.375% or 0.5% ropivacaine 15 mL, followed by continuous infusion of 0.15% ropivacaine 2 mL·hr(-1) with fentanyl 8 μg·hr(-1) postoperatively
Study: 25560712
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy stopped after negative D-dimer test results
Study: 25560712
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy stopped after negative D-dimer test results in men
Study: 25560712
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy stopped after negative D-dimer test results in women not associated with estrogen therapy
Study: 25560712
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy stopped after negative D-dimer test results in women associated with estrogen therapy
Study: 25563429
Drug: Lestaurtinib 140
Normalized name: Lestaurtinib
DrugBank: Lestaurtinib (DB06469)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lestaurtinib 140 mg twice daily (maximum tolerated dose)
Study: 25563429
Drug: Lestaurtinib (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lestaurtinib (doses lower than 140 mg)
Study: 25565635
Drug: Myoblast preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoblast preparations with genomic abnormalities
Study: 25566367
Drug: Culturally specific
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally specific group cognitive behavioral therapy (CS-CBT)
Study: 25566367
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group cognitive behavioral therapy (control)
Study: 25566367
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups receive transdermal nicotine patch (TNP) for 8 weeks
Study: 25566369
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and Mindfulness-Based Cognitive Therapy (MBCT)
Study: 25566391
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (16 sessions)
Study: 25566998
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (ADL) part of the Friedreich's Ataxia Rating Scale
Study: 25567425
Drug: Antipsychotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medications (olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone)
Study: 25567425
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (after 6 months)
Study: 25568347
Drug: R-MPV chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-MPV chemotherapy (rituximab, methotrexate 3.5 g/m(2), procarbazine, vincristine)
Study: 25572329
Drug: Panobinostat 30
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat 30 mg 3 times per week, every other week, in combination with bevacizumab 10 mg/kg every other week
Study: 25572917
Drug: Bortezomib 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.6 mg/m² intravenously once-weekly for six cycles with dexamethasone 40 mg on the day of and day after bortezomib
Study: 25574042
Drug: Silicone hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone hydrogel daily disposable lenses (SiHyDD)
Study: 25574042
Drug: Hydrogel daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel daily disposable lenses (HydDD)
Study: 25574088
Drug: TNBS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNBS treatment in rats
Study: 25574704
Drug: Maternal estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal estimated insulin resistance in the first half of pregnancy
Study: 25575538
Drug: Pomalidomide plus
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide plus low-dose dexamethasone (Pom-Dex)
Study: 25579459
Drug: Neoadjuvant anthracycline
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant anthracycline regimens followed by nanoparticle albumin-bound paclitaxel (nab-PTX) 260 mg/m² plus trastuzumab, administered every 3 weeks for 4 cycles.
Study: 25581108
Drug: Nonvitamin K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonvitamin K antagonist oral anticoagulants
Study: 25581108
Drug: Nonvitamin K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonvitamin K antagonist oral anticoagulants started early (median 4 days after stroke onset)
Study: 25585031
Drug: 2013 AHA/ACC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2013 AHA/ACC guidelines approach (maximization of statin therapy at high-intensity for patients aged ≤75 years and moderate- or high-intensity for patients >75 years)
Study: 25585031
Drug: Previous guidelines
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous guidelines approach (achievement of LDL-C target < 1.8 mmol/l, reduction of LDL-C ≥ 50% or intensification of statin)
Study: 25585528
Drug: Etravirine 400
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine 400 mg and darunavir/ritonavir 800/100 mg once-daily regimen
Study: 25586396
Drug: Psilocybin administered
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin administered orally in one or two supervised sessions in addition to Motivational Enhancement Therapy
Study: 25586726
Drug: Dosing recommendations
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing recommendations for EACA based on weight: weight <25 kg, 100 mg kg(-1) loading dose and 40 mg kg(-1) h(-1) infusion; weight ≤25 kg-<50 kg, 100 mg kg(-1) loading dose and 35 mg kg(-1) h(-1) infusion; weight ≥50 kg, 100 mg kg(-1) loading dose and 30 mg kg(-1) h(-1) infusion.
Study: 25586952
Drug: Escalating radiation
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating radiation dose with simultaneous integrated boost (SIB) to the pre-treatment 50% SUVmax area of the primary tumor, up to 70Gy
Study: 25589626
Drug: ChiLob7/4 (agonistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at 200 mg × 4 doses, administered by IV infusion weekly for 4 doses.
Study: 25589626
Drug: ChiLob7/4 (agonistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at doses above 16 mg.
Study: 25589626
Drug: ChiLob7/4 (agonistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at doses between 1.6 mg and 50 mg.
Study: 25589626
Drug: ChiLob7/4 (agonistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at doses that can be administered safely.
Study: 25589626
Drug: ChiLob7/4 (agonistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChiLob7/4 (agonistic anti-CD40 antibody) at doses from 50 mg upward.
Study: 25590177
Drug: Magnetic-controlled capsule
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic-controlled capsule endoscopy (MCE)
Study: 25590835
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day) and capecitabine (1000 mg/m2 twice daily on days 1-14)
Study: 25591040
Drug: Trabectedin 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 0.9 mg/m2 on day 1 and gemcitabine 700 mg/m2 on days 1 + 8, every 3 weeks
Study: 25591040
Drug: Trabectedin 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 0.7 mg/m2 plus gemcitabine 700 mg/m2